There is no single “drug of choice” for atrial fibrillation. The right medication depends on the treatment goal: controlling heart rate, restoring normal rhythm, or preventing stroke. Most people with atrial fibrillation end up on at least two medications, one to manage the irregular heartbeat itself and another to reduce stroke risk. Here’s how doctors decide which drugs to use and why.
Rate Control vs. Rhythm Control
The first decision in treating atrial fibrillation is whether to slow the heart rate down to a manageable level (rate control) or try to restore the heart’s normal rhythm (rhythm control). These two strategies aren’t mutually exclusive, and the approach can shift over time as the condition changes.
The 2023 ACC/AHA guidelines favor rhythm control when atrial fibrillation is caught early (within the first year), when symptoms like palpitations, fatigue, or shortness of breath are affecting daily life, or when heart failure is present. A landmark trial called EAST-AFNET 4 found that early rhythm control reduced the combined risk of death, stroke, and hospitalization by 25% compared to rate control alone. Rate control is generally preferred when someone has few or no symptoms and is living comfortably with the condition.
First-Line Drugs for Rate Control
Beta-blockers are the most commonly used first-line drugs for controlling heart rate in atrial fibrillation. They work by slowing electrical signals through the heart, which brings the rate down to a more normal range. The most frequently prescribed options include metoprolol, atenolol, bisoprolol, and propranolol. For most people, these are effective and well tolerated.
Calcium channel blockers, specifically diltiazem and verapamil, are the main alternative when beta-blockers aren’t a good fit. They also slow the heart rate but work through a different mechanism. One important caveat: these two drugs are off-limits for people with heart failure and reduced pumping function, because they can weaken the heart’s contractions further.
Digoxin is an older medication that still has a role, particularly in combination with a beta-blocker or when beta-blockers can’t be used. Its effect kicks in more slowly than other options, so it’s less useful when the heart rate needs to come down quickly.
Drugs for Restoring Normal Rhythm
Rhythm control medications (antiarrhythmics) are more powerful but also carry more risk. The choice depends heavily on whether the person has other heart conditions.
For people with structurally normal hearts and no history of heart attack, flecainide and propafenone are first-line options. They’re effective at maintaining a normal rhythm and are relatively straightforward to manage. However, they are not safe for anyone with a prior heart attack or weakened heart muscle, because they can trigger dangerous rhythms in those settings.
For people with coronary artery disease but preserved heart function, sotalol or dronedarone are typically chosen first. Both carry some risk of proarrhythmic effects, meaning they can occasionally cause new rhythm problems, so they require monitoring. Dronedarone is specifically not an option for people with decompensated heart failure.
Amiodarone is the most effective antiarrhythmic drug available and is reserved for situations where other options have failed or can’t be used safely. It’s one of the few rhythm control drugs appropriate for people with heart failure or significantly weakened heart function. The tradeoff is a long list of potential side effects affecting the thyroid, liver, lungs, skin, and eyes. People taking amiodarone need thyroid and liver function tests at baseline and every six months, along with lung monitoring if new breathing symptoms develop.
Dofetilide is another option for patients with heart failure or after a heart attack. It’s better at keeping normal rhythm than restoring it, and it requires a hospital stay for the first few doses so the heart rhythm can be closely monitored.
How Heart Failure Changes the Equation
Heart failure with reduced pumping function narrows the medication options considerably. For rate control, heart failure-specific beta-blockers are used cautiously, sometimes alongside digoxin. Calcium channel blockers like diltiazem and verapamil are contraindicated. Amiodarone can serve double duty as both a rate and rhythm control agent in this population, though it does have some effect on the heart’s contractile strength.
When atrial fibrillation occurs alongside acute, worsening heart failure, the typical approach is to stabilize the heart failure first with rate control, then consider rhythm control strategies once the patient is more stable. Catheter ablation, a procedure that targets the electrical source of the irregular rhythm, is increasingly considered early for people with both conditions.
Stroke Prevention: The Other Essential Drug
Regardless of whether rate or rhythm control is chosen, most people with atrial fibrillation also need a blood thinner to prevent stroke. Atrial fibrillation allows blood to pool in the heart’s upper chambers, which can form clots that travel to the brain.
The decision to start anticoagulation is based on the CHA₂DS₂-VASc score, which tallies risk factors like age, high blood pressure, diabetes, prior stroke, and heart failure. Men with a score of 2 or higher (or women with 3 or higher) are recommended for long-term anticoagulation. Those at the lowest risk, a score of 0 for men or 1 for women, generally don’t need a blood thinner.
Direct oral anticoagulants (DOACs) have largely replaced warfarin as the preferred blood thinners for atrial fibrillation. They have fewer food and drug interactions, don’t require regular blood draws to check levels, and provide more predictable protection. In studies of patients with atrial fibrillation and valve disease (excluding mechanical valves), DOACs reduced the risk of stroke or systemic clots by 30% and bleeding by 28% compared to warfarin.
Warfarin remains the only option for two specific groups: people with mechanical heart valves and those with moderate to severe rheumatic mitral valve disease. For everyone else, a DOAC is the standard choice.
Acute Episodes and Emergency Settings
When atrial fibrillation causes a dangerously fast heart rate, intravenous medications are used to bring it under control quickly, then switched to oral drugs for ongoing management. IV beta-blockers and calcium channel blockers act faster than IV digoxin, making them the go-to options in most acute situations. IV amiodarone is useful for critically ill patients because it controls rate with relatively little impact on blood pressure.
One important exception is atrial fibrillation with an accessory pathway (a condition called pre-excited atrial fibrillation). Standard rate control drugs can be dangerous here because they may speed conduction through the abnormal pathway. In these cases, procainamide or amiodarone is used instead to slow the rate safely.